Among them, E2F1 ranked the first in both BC and Degree (Figures 5(b) and 5(c)), and E2F1 was thus selected as the core gene of dehydrovomifoliol in NAFLD treatment for subsequent experiments. The gene discussed is E2F1; the disease is metabolic dysfunction-associated steatotic liver disease.